The Quantellect read.As of Nov 19, 2026, 6 active firms cover Jade Biosciences, Inc: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $25.00 to $77.00 (about 3.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $46.83 sits 203% above the current $15.48. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.60 next quarter toward $-2.26 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$46.83
+202.5% upside
Average target across 6 active firms as of Nov 19, 2026 vs $15.48 current
Highest Target$77.00
Average Target$46.83
Lowest Target$25.00
Detailed analyst forecasts for JBIO
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 6 of 6 active firms rate JBIO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
JBIO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.60
Range $-0.72 – $-0.45 · 5 analysts · +6% YoY
Next period, 5 analysts expect Jade Biosciences, Inc. to earn $-0.60 a share (range $-0.72 – $-0.45), versus $-0.57 a year earlier. Full-year consensus is $-2.13, growing to $-2.26 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Jade Biosciences, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on JBIO.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$47.00+203.6% to target
Overall win rate
48%
+ Follow
#2
Laura Chico
Wedbush · Rank #55
Buy
$47.00+203.6% to target
Overall win rate
46%
+ Follow
#3
Julian Harrison
BTIG · Rank #183
Buy
$77.00+397.4% to target
Overall win rate
41%
+ Follow
#4
Arthur He
HC Wainwright & Co. · Rank #198
Buy
$55.00+255.3% to target
Overall win rate
50%
+ Follow
#5
Vamil Divan
Guggenheim · Rank #211
Buy
$47.00+203.6% to target
Overall win rate
48%
+ Follow
JBIO stock forecast FAQ
What is JBIO's average 12-month price target?+
The 6 active firms with a live target average $46.83 for Jade Biosciences, Inc. over the next 12 months, ranging from a $77.00 high to a $25.00 low, as of Nov 19, 2026.
Is JBIO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for JBIO?+
The Street-high target is $77.00 (BTIG), and the Street-low is $25.00 (Clear Street). The average of all 6 active-firm targets is $46.83.
How many active Wall Street firms cover JBIO?+
6 active firms have a recognized rating on Jade Biosciences, Inc. as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering JBIO?+
Among analysts who currently cover JBIO, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $47.00 target.
What is Jade Biosciences, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.60 per share (range $-0.72 – $-0.45) across 5 analysts. Full-year EPS is projected at $-2.13, rising to $-2.26 the following year.
How much revenue is Jade Biosciences, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading JBIO lately?+
As of Nov 19, 2026, 6 of 6 active firms rate JBIO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their JBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.